Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population

Interethnic variability in the drug-metabolizing capacity of CYP450 enzymes may lead to discrepancies in the relationship between genotypes and phenotypes worldwide. The present study was aimed to analyze for the first time whether there is a relationship between clinically relevant CYP450 genetic polymorphisms and their drug oxidation capacity (metabolic phenotype) in a population of healthy Nicaraguan volunteers. Two hundred and twelve participants were genotyped for CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and their actual metabolic phenotype (evaluated by the Metabolic Ratio, MR) was analyzed by using the CEIBA cocktail approach. The results showed the wide interindividual variability in all the studied enzymes and a significant difference (p < 0.004) in the activity of CYP1A2 between male and female subjects. The number of CYP2C19 (p < 0.0001) and CYP2D6 (p < 0.0001) active alleles were shown inversely correlated with their corresponding MR, although there were marked genotype-phenotype discrepancies. There was an actual enzyme capacity overlapping (MR) between genotypically Poor (gPMs) and Extensive Metabolizers (gEMs) of 3.14% subjects for CYP2D6 and 0.94% for CYP2C9. Similarly, there was an overlapping for metabolic phenotypes of 11.48% of genotypically ultrarapid metabolizers (gUMs) for CYP2C19 and 2.09% for CYP2D6 and gEMs. Therefore, the current approach for metabolic phenotype prediction based just on genotype does not predict properly for all individuals within this Nicaraguan Mestizo population, thus representing a potential barrier for the clinical implementation of personalized medicine in this region. However, it is necessary to improve the prediction of phenotype from genotype in order to improve the pharmacogenetic implementation in populations with specific ethnic backgrounds.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:21

Enthalten in:

The pharmacogenomics journal - 21(2021), 2 vom: 06. Apr., Seite 140-151

Sprache:

Englisch

Beteiligte Personen:

de Andrés, Fernando [VerfasserIn]
Altamirano-Tinoco, Catalina [VerfasserIn]
Ramírez-Roa, Ronald [VerfasserIn]
Montes-Mondragón, Carlos F [VerfasserIn]
Dorado, Pedro [VerfasserIn]
Peñas-Lledó, Eva M [VerfasserIn]
LLerena, Adrián [VerfasserIn]

Links:

Volltext

Themen:

9035-51-2
Cytochrome P-450 Enzyme System
Journal Article
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 12.01.2022

Date Revised 12.01.2022

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1038/s41397-020-00190-9

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM315944285